After successful consideration among the FAMHP, the National Institute for Health and Disability Insurance (RIZIV-INAMI) and the manufacturer Therabel, the manufacturer has decided to continue to produce the drug Marevan. The FAMHP calls on pharmacists and patients to not order unnecessary inventories of the drug so that the drug will remain available for all patients.
The FAMHP was notified by the manufacturer Therabel of the planned discontinuation of the commercialization of Marevan (warfarin) as of March 2019.
Marevan (warfarin) is an anti-coagulant agent. It is used to make the blood more liquid to prevent the formation of clots (thrombosis) or to dissolve existing clots to prevent them migrating into the blood vessels (embolism).
Due to the risk of bleeding and/or blood clots when changing treatment with Marevan, the FAMHP, together with the RIZIV has sought a solution in the interest of the patient to continue to guarantee the availability of warfarin in Belgium even after March 2019. After a constructive consultation, the manufacturer Therabel confirms that Marevan will remain on the market even after March 2019. The manufacturer will make the efforts necessary to guarantee the continuity of availability.
The FAMHP calls on pharmacists and patients to not order unnecessary inventories of the drug so that the drug will remain available for all patients.
More information on Marevan.